Comparative Pharmacology
Head-to-head clinical analysis: FOLICET versus NASCOBAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLICET versus NASCOBAL.
FOLICET vs NASCOBAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folic acid is reduced to tetrahydrofolate (THF) through the enzyme dihydrofolate reductase. THF is a cofactor in one-carbon transfer reactions involved in purine and pyrimidine synthesis, and amino acid metabolism, essential for DNA synthesis and cell division.
Vitamin B12 (cyanocobalamin) is a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis.
1 mg orally once daily. For treatment of megaloblastic anemia, up to 5 mg daily initially.
1 spray (500 mcg) intranasally once weekly.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in adults with normal renal function; may be prolonged up to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 6 days (depot effect due to slow release from injection site); for intramuscular doses, terminal elimination half-life is about 6 days due to gradual absorption
Primarily renal elimination: approximately 80% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal excretion accounts for <15%.
Primarily renal (60-80% as unchanged drug), biliary/fecal (5-10%)
Category C
Category C
Vitamin
Vitamin